We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2026 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

IBM Plans to Devise Faster, Less Expensive Sequencing Technology

By LabMedica International staff writers
Posted on 26 Oct 2009
IBM (Armonk, NY, USA) is in the process of slashing the cost of sequencing a genome, now focused on the US$1,000 mark, jumping into a leading position in the biotech revolution.

IBM already has a supercomputer project in position to model biologic processes. Now its combining its supercomputer capacity with its expertise in material science and semiconductors to create a new, much faster sequencing machine that can reduce the cost of mapping the human genome to only $100. Moreover, as scientists continue to systematically clarify the role of genetics in disease, individuals will be able to afford a thorough reading of their risk of disease while drug developers will be able to operate with a clearly devised map to disease targets.

"More and more of biology is becoming an information science, which is very much a business for IBM,” Ajay Royyuru, senior manager for IBM's computational biology center at its Thomas J. Watson Laboratory (Yorktown Heights, NY, USA), recently told the New York Times. Eight years ago sequencing the first genome consumed a billion dollars. The current cost is between $5,000 and $50,000, and rapidly declining.

Related Links:

IBM



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
New
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Clinical Chemistry Analyzer
Envoy 500+

Latest Industry News

Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
26 Oct 2009  |   Industry

Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
26 Oct 2009  |   Industry

Bruker Expands NGS Capabilities for Sepsis and Bloodstream Infections
26 Oct 2009  |   Industry



PURITAN MEDICAL